Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Liabilities from Discontinued Operations (2016 - 2018)

Soleno Therapeutics (SLNO) has disclosed Liabilities from Discontinued Operations for 2 consecutive years, with 110000.0 as the latest value for Q3 2018.

  • On a quarterly basis, Liabilities from Discontinued Operations changed N/A to 110000.0 in Q3 2018 year-over-year; TTM through Sep 2018 was 110000.0, a N/A change, with the full-year FY2017 number at 225000.0, changed N/A from a year prior.
  • Liabilities from Discontinued Operations was 110000.0 for Q3 2018 at Soleno Therapeutics, down from 225000.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 225000.0 in Q4 2017 to a low of 110000.0 in Q3 2018.